REPROCELL’s Company News

Press releases, public announcements, and associated material.

Recent Company News

13 May 2019 — Press Release: REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders.

29 April 2019 — Announcement: Market Research Updates has released a report about New Developments with Operational Updates in Cryogenic Biobanking Services Market with top leading players. The report covers and analyzes the Cryogenic Biobanking Services market and its major vendors, including REPROCELL’s brands in this space, the companies formerly known as BioServe and Stemgent.

24 April 2019 — REPROCELL and Hanugen to custom manufacture clinical grade oligos for gene therapy

8 April 2019 — REPROCELL USA Inc. Achieves Quality Management ISO9001:2015 Certification

14 March 2019 — UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine

12 March 2019 — REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development

28 February 2019 — REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories

1 February 2019 — Appointment of New Distributor in China

10 October 2018 — ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production (PDF)

9 October 2018 — REPROCELL announces the launch of a cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: SNIPER

1 August 2018 — Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan

26 April 2018 — Acquisition of BioServe Biotechnologies India Pvt. Ltd.


Older Company News

15 January 2018 — REPROCELL Launches New Global Website (PDF)

29 November 2017 — REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao (PDF)

29 November 2017 — Presentation: Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao (PDF)

8 November 2017 — REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

10 August 2017 — REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of Its Predictive Drug Discovery Services (PDF)

10 August 2017 — Nicola Sturgeon, First Minister of Scotland, Opens REPROCELL European Headquarters in Glasgow (PDF)

24 May 2017 — REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India (PDF)

13 April 2017 — REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery (PDF)

14 February 2017 — REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan

7 February 2017 — Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination

22 November 2016 — Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products

21 November 2016 — Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy (PDF)

16 November 2016 — Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

11 November 2016 — Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy (PDF)

16 September 2016 — REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex

14 January 2016 — Alvetex in Space

24 November 2015 — REPROCELL Acquires Biopta to Expand Its Drug Discovery Services (PDF)

24 November 2015 — REPROCELL Inc.: Regarding the synergy effect of making Biopta Limited a wholly-owned subsidiary (Supplemental information) (PDF)

11 November 2015 — Regarding the synergy effect of making Biopta Limited a wholly-owned subsidiary (PDF)

18 November 2015 — Notice concerning the publication of a paper concerning “3D culture model construction of mouse neurons” from a company in our group in the international neuroscience journal ‘Neuroscience Letters’ (PDF)

16 November 2015 — A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality (PDF)

4 November 2015 — Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells (PDF)

19 October 2015 — The REPROCELL Group announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by this corporate group and others (PDF)

14 October 2015 — The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal (PDF)

24 September 2015 — Joint Announcement with Ajinomoto Co., Inc. Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells (PDF)

8 September 2015 — REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells (PDF)

26 August 2015 — Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University: New high-performance cryopreservation solution for human ES/iPS cells used in regenerative medicine Notice of the commencement of sales of “ReproCryo DMSO free” (PDF)

14 August 2015 — Commit to Regenerative Medicine (PDF)

14 August 2015 — Presentation: REPROELL Inc.: Advancing Towards Regenerative Medicine (PDF)

14 August 2015 — Announcement: REPROCELL’s project, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells”, has been chosen to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016). The subsidy will be added to the income statement as non-operating income (PDF)

29 July 2015 — Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient” (PDF)

21 July 2015 — Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells (PDF)

1 July 2015 — Announcement: FY 2014-2015 Grant (Additional) for Manufacturing, Commerce, and Service Innovation Has Been Awarded to “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem Cells for Applications in Drug Discovery” (PDF)

30 June 2015 — Stemgent, a REPROCELL Group Company Launches a New High Performance Self-replicative RNA Reprogramming Kit (PDF)

4 June 2015 — REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells (PDF)

5 March 2015 — New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system

9 September 2014 — REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA) (PDF)

5 August 2014 — Stem Cell Company REPROCELL (Japan) Acquires 3D Cell Culture Company Reinnervate (UK) and Human Tissue Supplier BioServe (USA) (PDF)

27 June 2012 — Top award for 3D cell culture pioneer, Stefan Przyborski, of Reinnervate Ltd

Top